aminogluthemide (Cytadren)

Tradename: Cytadren. Indications: 1) suppression of adrenal function in selected patients with Cushing's syndrome 2) postmenopausal women with advanced breast carcinoma 3) patients with metastatic prostate cancer Dosage: 1) start: 250 mg PO every 6 hours 2) increase up to 2 g/day divided BID-TID (to decrease incidence of nausea/vomiting) Tabs: 250 mg Adverse effects: 1) common (> 10%) - headache, dizziness, drowsiness & lethargy, ataxia, lupus-like syndrome, rash, nausea/vomiting, anorexia, cholestatic jaundice, myalgia, nephrotoxicity, pulmonary alveolardamage 2) less common (1-10%) - orthostatic hypotension, tachycardia, hirsutism, adrenocortical insufficiency 3) rare - neutropenia, leukopenia, thrombocytopenia, pancytopenia, agranulocytosis * most adverse effects diminish in incidence & severity after 2-6 weeks of therapy Drug interactions: 1) aminophylline 2) corticosteroids 3) theophylline 4) warfarin

Properties

MISC-INFO: pregnancy-category D

References

Kaiser Permanente Northern California Regional Drug Formulary, 1998